Skip to main content

Nasal Polyps News

News
02/25/2022
Jolynn Tumolo
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment with a monoclonal antibody for asthma, atopic dermatitis, and nasal polyps also saw improvements in concomitant eosinophilic esophagitis symptoms, according to a retrospective chart review.
Patients receiving treatment...
02/25/2022
First Report Managed Care
News
10/27/2021
Jolynn Tumolo
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat population of patients with [chronic rhinosinusitis with nasal polyps] with comorbid asthma, the results presented here illustrate that dupilumab as an add-on to the standard-of-care mometasone furoate nasal spray...
“In the difficult-to-treat...
10/27/2021
First Report Managed Care
News
09/27/2019
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and symptom severity in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), according to results from two randomized clinical trials. ...
Dupilumab reduces polyp size and...
09/27/2019
First Report Managed Care
News
07/29/2019
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that patients with chronic rhinosinusitis with nasal polyps experience a significantly lower health-related quality of life.
Recent research found that...
07/29/2019
First Report Managed Care
News
06/26/2019
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron Pharmaceuticals and Sanofi), is the first treatment approved by the FDA for the treatment of inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupixent (dupilumab; Regeneron...
06/26/2019
First Report Managed Care